Although targeted therapy has evolved in the last years and significantly improved the prognosis of patients with cutaneous melanoma, its use in vulvar and vaginal melanomas is still limited by the different mutagenic profiles involving fewer BRAF mutations and more c-KIT, NF1 and SF3B1 mutations [91,112]. This evidence concerns the gene KIT and cutaneous melanoma.